Fake testimonials, no pharmacy and an FDA warning: how Medvi built a $1.8 billion telehealth company in the gaps between regulators

The New York Times published a profile of the company Medvi earlier this month, celebrating it as an example of what AI could help a single person do: build a telehealth company its founder projects will be worth $1.8 billion this year despite a closing loophole for telehealth companies selling compounded versions of popular metabolic… The post Fake testimonials, no pharmacy and an FDA warning: how Medvi built a $1.8 billion telehealth company in the gaps between regulators appeared first on Drug Discovery and Development.

Continue reading →